579 related articles for article (PubMed ID: 24888801)
21. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Vincent Rajkumar S
Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
[TBL] [Abstract][Full Text] [Related]
23. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
25. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
26. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
28. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
[No Abstract] [Full Text] [Related]
29. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
[No Abstract] [Full Text] [Related]
30. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
31. [Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Nagamachi Y; Yamauchi N; Muramatsu H; Miyajima N; Inomata H; Okamoto T; Nozawa E; Gotoh Y; Koyama R; Ihara K; Nishisato T; Kato J
Rinsho Ketsueki; 2015 Mar; 56(3):323-8. PubMed ID: 25876787
[TBL] [Abstract][Full Text] [Related]
32. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
33. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
34. Periodic fever as the only presenting symptom of multiple myeloma in a young man.
Trakatelli C; Kintiraki E; Koratzis J; Gamvrili L; Kotsis V; Sion M
J Biol Regul Homeost Agents; 2008; 22(4):263-5. PubMed ID: 19036229
[TBL] [Abstract][Full Text] [Related]
35. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
36. New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Caldini A; Nozzoli C; Terreni A; Staderini M; Berardi M; Biagioli T; Brogi M; Bosi A
Clin Chem Lab Med; 2016 Jun; 54(6):991-5. PubMed ID: 26581069
[TBL] [Abstract][Full Text] [Related]
37. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
[TBL] [Abstract][Full Text] [Related]
38. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
[TBL] [Abstract][Full Text] [Related]
39. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
[TBL] [Abstract][Full Text] [Related]
40. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
